Linking the Autotaxin-LPA Axis to Medicinal Cannabis and the Endocannabinoid System.

ABSTRACT: Over the past few decades, many current uses for cannabinoids have been described, ranging from controlling epilepsy to neuropathic pain and anxiety treatment. Medicines containing cannabinoids have been approved by both the FDA and the EMA for the control of specific diseases for which there are few alternatives. However, the molecular-level mechanism of action of cannabinoids is still poorly understood. Recently, cannabinoids have been shown to interact with autotaxin (ATX), a secreted lysophospholipase D enzyme responsible for catalyzing lysophosphatidylcholine (LPC) to lysophosphatidic acid (LPA), a pleiotropic growth factor that interacts with LPA receptors. In addition, a high-resolution structure of ATX in complex with THC has recently been published, accompanied by biochemical stud

SUBMITTER: Eymery MC 

PROVIDER: S-EPMC10970320 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature